Sanuwave Health (SNWV) Planet MicroCap Las Vegas 2026 summary
Event summary combining transcript, slides, and related documents.
Planet MicroCap Las Vegas 2026 summary
18 Jun, 2026Market overview and industry trends
Wound care is a $76 billion U.S. market, driven by an aging population and increasing chronic wounds.
The industry is shifting toward evidence-based medicine and cost-per-episode analysis, with payers driving changes.
Recent CMS reimbursement cuts in the skin substitute space have caused significant disruption, forcing providers to adapt.
Larger, more sophisticated providers are emerging, focusing on route density and holistic patient care.
Hospitals are increasingly integrating mobile wound care to improve outcomes and reduce readmissions.
Product positioning and clinical evidence
UltraMIST is a non-contact, non-thermal ultrasound device with FDA clearance and a nationwide CMS code.
The system achieves 2x-3x faster healing rates and 80% pain reduction compared to standard care, supported by 18 peer-reviewed studies and 8 RCTs.
Over 2 million procedures have been performed, with 325,000 in the last year.
The device is highly portable, easy to use, and designed for a wide range of care settings.
Only product with high-quality clinical evidence for efficacy in its category, enabling reliable reimbursement.
Business model and financial performance
Operates a razor/razor blade model: systems list at $30,000, single-use applicators at $100, with 55%-65% of revenue from consumables.
1,382 active systems in the field at Q1, with 1.5% market penetration and significant room for growth.
2025 revenue projected at $44 million, with $9.3 million in Q1 and gross margins in the high 70s.
2024 saw 35% year-over-year revenue growth and a 30% cash EBITDA margin.
Margins between systems and consumables are similar, with further improvements expected from new manufacturing processes.
Latest events from Sanuwave Health
- Innovative ultrasound wound care system drives growth with high margins and strong clinical results.SNWV
Investor presentation17 Jun 2026 - Director elections, auditor ratification, and executive pay were voted on; results pending.SNWV
AGM 202611 Jun 2026 - Q1 2026 set a revenue record with improved net loss and strong outlook for continued growth.SNWV
Q1 202613 May 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance focus.SNWV
Proxy filing29 Apr 2026 - Key votes include director elections, auditor ratification, and executive pay approval.SNWV
Proxy filing29 Apr 2026 - Record 2025 revenue and profit, with strong UltraMIST sales and robust 2026 growth outlook.SNWV
Q4 202527 Mar 2026 - Record Q2 revenue and net income, with strong Q3 growth expected but ongoing capital risks.SNWV
Q2 20242 Feb 2026 - Merger deadline extended, Cboe listing targeted, and 50% revenue growth forecast.SNWV
M&A Announcement31 Jan 2026 - Q3 revenue up 89% to $9.4M, margin gains, but going concern risks persist.SNWV
Q3 202415 Jan 2026